Jane Street’s Spyre Therapeutics SYRE Stock Holding History

Jane Street’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$258K	Buy	+2,909	New	+$212K	﹤0.01%	9534
2025 Q4	–	Sell	-96,057	Closed	-$1.61M	–	12350
2025 Q3	$1.61M	Buy	+96,057	New	+$1.57M	﹤0.01%	5339
2024 Q4	–	Sell	-20,641	Closed	-$607K	–	10558
2024 Q3	$607K	Buy	20,641 +9,090	+79%	+$253K	﹤0.01%	6851
2024 Q2	$272K	Buy	11,551 +4,341	+60%	+$146K	﹤0.01%	7953
2024 Q1	$273K	Buy	+7,210	New	+$209K	﹤0.01%	7700
2023 Q3	–	Sell	-2,171	Closed	-$24.5K	–	9366
2023 Q2	$24.5K	Buy	2,171 +460	+27%	+$2.18K	﹤0.01%	8335
2023 Q1	$12.4K	Buy	+1,711	New	+$18.8K	﹤0.01%	8717
2020 Q4	–	Sell	-475	Closed	-$84K	–	8104
2020 Q3	$84K	Sell	475 -24	-5%	-$4.44K	﹤0.01%	6799
2020 Q2	$115K	Buy	+499	New	+$95K	﹤0.01%	6664

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jane Street's SYRE Position: Q2 2026 in Review

Jane Street opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 2,909 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #9534 among its holdings. This is a return to the name: Jane Street previously reported a position in SYRE as recently as Q3 2025.

Jane Street first reported a position in SYRE in Q2 2020 and has held it in 9 quarters since. The position peaked at $1.61M in Q3 2025. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Jane Street held 2,909 shares of Spyre Therapeutics worth $258K as of Q2 2026.
Spyre Therapeutics was a new Jane Street position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #9534 holding.
Jane Street first reported a position in Spyre Therapeutics in Q2 2020 and has held it in 9 quarters since.
Jane Street's Spyre Therapeutics position peaked at $1.61M in Q3 2025.
266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.